Peptides in the emergency department need clinician training says OMED speaker

LAS VEGAS (Peptide Zone) An emergency physician told a national osteopathic meeting that clinicians must learn to recognise problems linked to peptides in the emergency department. Kenneth L. Frye Jr., DO, of TeamHealth, spoke at OMED, held Oct. 22 to 25, and expanded on his talk in an interview with Healio published Oct. 28. He said GLP 1 drugs cause most peptide visits, while many doctors know little about injectables such as BPC 157 and TB 500. Some of his regulatory remarks do not match current labels, and long term data on most of these compounds are missing.

Why ED clinicians are told to learn peptides

Frye presented a session on peptide therapy written for emergency medicine physicians, according to the reference list in the Healio interview with Frye. His central point was a knowledge gap about peptides in the emergency department. He said doctors know how GLP 1 drugs present but show "a really strong unfamiliarity" with BPC 157, TB 500, sermorelin, ipamorelin and tesamorelin. The interview covered which products emergency staff see, what signs to look for and how to counsel people who use unapproved compounds. Healio said Frye reported no relevant financial disclosures. The piece is the view of one clinician. It reports no case counts, no survey of hospitals and no trial data, so it describes his experience rather than a measured national trend.

Frye based his call for training on demand. He said peptides "are not going away" and that the market is projected to keep growing, though the interview gave no figure and this site has not checked one. He compared the task to the way emergency doctors already study cocaine, heroin and methamphetamine. Clinicians, he said, "can only better take care of patients by learning about the things that they're doing." Other reports point in the same direction. University of Queensland researchers said people injecting peptides bought online rarely see themselves as drug injectors, and NSW Health warned hospitals of rising presentations, as this site reported in its story on needle programs and safety advice.

GLP 1 side effects and the Wolverine Stack

Frye said GLP 1 drugs are by far the most common peptides that emergency teams will meet. He listed nausea, vomiting, constipation and abdominal pain as the usual complaints among patients who take them. These GLP 1 side effects are familiar to most clinicians, which gives them a starting point. The harder cases, he said, come from other groups of peptides. He named the so called Wolverine Stack, a combination of BPC 157 and TB 500 that he described as very common and popular among users. He said he has personally seen patients in his department who took sermorelin. He also pointed to other growth hormone related products, naming ipamorelin, tesamorelin, insulin like growth factor 1 and a long arginine 3 form of that hormone.

Frye called melanotan the most dangerous peptide on his list and cited multiple documented emergency cases of priapism and rhabdomyolysis linked to it.

Frye called melanotan the most dangerous peptide on his list and cited multiple documented emergency cases of priapism and rhabdomyolysis linked to it. Priapism is a prolonged erection, and rhabdomyolysis is the breakdown of muscle tissue. He described both as highly dangerous presentations. The interview gave no count of melanotan priapism or muscle injury cases and did not cite the reports, and this site has not verified a number. Frye advised clinicians to learn the main peptide categories first and then the specific products that carry the most serious risks. In practice, that may mean asking patients directly about injected products, since a person may not list a peptide bought online as a medicine. That last point is consistent with the Queensland finding that many users do not see themselves as people who inject drugs.

Unapproved peptides and what the labels say

Frye argued that many unapproved peptides also have approved uses. He said sermorelin is approved for growth hormone deficiency in children, that tesamorelin is approved for a condition linked to HIV and that SS 31 was recently cleared by the FDA. The record is more complicated. The commercial sermorelin product, Geref, was discontinued in 2008 and is no longer available as a prescription medicine, according to the U.S. Anti-Doping Agency. Tesamorelin, sold as Egrifta SV, is labelled to reduce excess abdominal fat in adults with HIV and lipodystrophy, according to its prescribing information, not to treat dyslipidemia as the interview stated. The same label says its long term cardiovascular safety has not been established.

SS 31 is the research name for elamipretide. Stealth BioTherapeutics said on Sept. 19, 2025, that the FDA granted accelerated approval to Forzinity to improve muscle strength in people with Barth syndrome, a rare mitochondrial disease. The company said continued approval may depend on a confirmatory trial. Frye called it a metabolic peptide, but the approved use is narrow. His wider point still holds: a label for one disease does not cover the uses people pursue on their own. Approval also applies to a specific product made to a set standard. A vial sold online under the same name carries no such assurance, and none of these approvals extends to BPC 157, TB 500 or melanotan.

Counselling advice and what is still unknown

On counselling, Frye said the standard advice for unapproved peptides from unknown sources should be "don't take." He accepted that many people will use them anyway. His fallback was care from a physician who knows peptides and works with a regulated pharmacy, which he said may offer better purity and fewer contaminants, while noting the compound itself may still lack FDA approval. The rules here are shifting. An interim HHS policy lets licensed pharmacies compound BPC 157 and five other peptides under set conditions, although FDA reviewers had advised against listing them and none is an approved drug. Pharmacy compounding is not the same as FDA approval, which rests on trial evidence of safety and effectiveness.

Product quality outside pharmacies is a documented concern. Customs tests in Iceland found many seized peptide vials did not contain what their labels claimed, as this site reported alongside rising insulin syringe sales. Frye also urged regular lab work and physician visits for people who use these products, so that harm is caught early. Much remains unknown about peptides in the emergency department. Healio noted that the long term effects of many peptides are poorly understood. The interview offered no data on how often peptide users reach emergency care in the United States, which products cause the most visits or what outcomes follow. Those figures would show whether one physician's experience reflects a wider pattern.

Conclusion

Frye's message at OMED 2026 was practical: learn the main peptide classes, know which products carry the gravest risks and ask patients what they inject. The case for training on peptides in the emergency department rests for now on clinical experience, not national surveillance data. Some approval claims in the interview do not match current labels, and long term safety data for most unapproved peptides are missing. This report is research news, not medical advice.